Capital World Investors Editas Medicine, Inc. Transaction History

Capital World Investors

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $5.31 Million - $8.11 Million	-200,000 Reduced 15.38%	1,100,000 $29.2 Million
Q1 2021 May 14, 2021	SELL	$39.71 - $90.58 $3.97 Million - $9.06 Million	-100,000 Reduced 7.14%	1,300,000 $54.6 Million
Q4 2020 Feb 12, 2021	SELL	$27.07 - $84.35 $9.75 Million - $30.4 Million	-360,000 Reduced 20.45%	1,400,000 $98.2 Million
Q2 2019 Aug 14, 2019	SELL	$20.48 - $27.76 $3.48 Million - $4.72 Million	-170,000 Reduced 8.81%	1,760,000 $43.5 Million
Q4 2018 Feb 14, 2019	SELL	$18.19 - $31.79 $1.86 Million - $3.24 Million	-102,000 Reduced 5.02%	1,930,000 $43.9 Million
Q3 2018 Nov 14, 2018	SELL	$27.65 - $38.39 $4.2 Million - $5.84 Million	-152,000 Reduced 6.96%	2,032,000 $64.7 Million
Q1 2018 May 15, 2018	BUY	$29.84 - $44.08 $12.4 Million - $18.2 Million	414,000 Added 23.39%	2,184,000 $72.4 Million
Q3 2017 Nov 14, 2017	BUY	$15.81 - $24.01 $28 Million - $42.5 Million	1,770,000	1,770,000 $42.5 Million

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $82.5M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

Stay updated on Capital World Investors with notifications on news.